Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: A case study

Jane Bryce, Martina Bauer, Peyman Hadji

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: In order to reduce the risk of recurrence, adjuvant treatment with an aromatase inhibitor (AI) is recommended for postmenopausal women following surgery for hormone receptor-positive breast cancer. AIs are associated with improved disease-free survival compared with tamoxifen. The adverse events associated with AIs resemble those of menopause, such as bone density loss and musculoskeletal symptoms. Purpose: We examine the case of a postmenopausal woman who was prescribed anastrozole, a nonsteroidal AI, as adjuvant therapy following surgery for estrogen and progesterone receptorpositive (ER and PgR+) breast cancer. Methods and sample: A 58-year-old postmenopausal woman diagnosed with ER and PgR+ breast cancer was prescribed anastrozole as adjuvant therapy following a right-inferior quadrantectomy. After experiencing joint pain and stiffness, she was prescribed paracetamol and a topical nonsteroidal anti-inflammatory drug. She was also counseled on nonpharmacological interventions. However, she continued to experience symptoms, and reported that she was not taking anastrozole regularly. Results: The case study patient ultimately found relief by switching to letrozole, another aromatase inhibitor. This approach is supported by recent studies examining the benefits of switching strategies between aromatase inhibitors in order to relieve symptoms of arthralgia/myalgia. Conclusions: Both adherence and strategies for managing aromatase inhibitor-associated arthralgia are key to deriving maximal clinical benefit from AI therapy. Switching from one aromatase inhibitor to another may provide a viable option in managing adverse events and enhancing adherence to medication.

Original languageEnglish
Pages (from-to)105-111
Number of pages7
JournalCancer Management and Research
Volume4
Issue number1
DOIs
Publication statusPublished - Mar 28 2012

Fingerprint

Aromatase Inhibitors
Arthralgia
Breast Neoplasms
letrozole
Medication Adherence
Myalgia
Tamoxifen
Therapeutics
Acetaminophen
Menopause
Bone Density
Disease-Free Survival
Progesterone
Estrogens
Anti-Inflammatory Agents
Hormones
Recurrence
Pharmaceutical Preparations
anastrozole

Keywords

  • Adherence
  • Anastrozole
  • Aromatase inhibitor
  • Arthralgia
  • Breast cancer
  • Letrozole

ASJC Scopus subject areas

  • Oncology

Cite this

Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer : A case study. / Bryce, Jane; Bauer, Martina; Hadji, Peyman.

In: Cancer Management and Research, Vol. 4, No. 1, 28.03.2012, p. 105-111.

Research output: Contribution to journalArticle

@article{6f9cf00ff7ca4737ad5a697e76db5ced,
title = "Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: A case study",
abstract = "Background: In order to reduce the risk of recurrence, adjuvant treatment with an aromatase inhibitor (AI) is recommended for postmenopausal women following surgery for hormone receptor-positive breast cancer. AIs are associated with improved disease-free survival compared with tamoxifen. The adverse events associated with AIs resemble those of menopause, such as bone density loss and musculoskeletal symptoms. Purpose: We examine the case of a postmenopausal woman who was prescribed anastrozole, a nonsteroidal AI, as adjuvant therapy following surgery for estrogen and progesterone receptorpositive (ER and PgR+) breast cancer. Methods and sample: A 58-year-old postmenopausal woman diagnosed with ER and PgR+ breast cancer was prescribed anastrozole as adjuvant therapy following a right-inferior quadrantectomy. After experiencing joint pain and stiffness, she was prescribed paracetamol and a topical nonsteroidal anti-inflammatory drug. She was also counseled on nonpharmacological interventions. However, she continued to experience symptoms, and reported that she was not taking anastrozole regularly. Results: The case study patient ultimately found relief by switching to letrozole, another aromatase inhibitor. This approach is supported by recent studies examining the benefits of switching strategies between aromatase inhibitors in order to relieve symptoms of arthralgia/myalgia. Conclusions: Both adherence and strategies for managing aromatase inhibitor-associated arthralgia are key to deriving maximal clinical benefit from AI therapy. Switching from one aromatase inhibitor to another may provide a viable option in managing adverse events and enhancing adherence to medication.",
keywords = "Adherence, Anastrozole, Aromatase inhibitor, Arthralgia, Breast cancer, Letrozole",
author = "Jane Bryce and Martina Bauer and Peyman Hadji",
year = "2012",
month = "3",
day = "28",
doi = "10.2147/CMAR.S29448",
language = "English",
volume = "4",
pages = "105--111",
journal = "Cancer Management and Research",
issn = "1179-1322",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer

T2 - A case study

AU - Bryce, Jane

AU - Bauer, Martina

AU - Hadji, Peyman

PY - 2012/3/28

Y1 - 2012/3/28

N2 - Background: In order to reduce the risk of recurrence, adjuvant treatment with an aromatase inhibitor (AI) is recommended for postmenopausal women following surgery for hormone receptor-positive breast cancer. AIs are associated with improved disease-free survival compared with tamoxifen. The adverse events associated with AIs resemble those of menopause, such as bone density loss and musculoskeletal symptoms. Purpose: We examine the case of a postmenopausal woman who was prescribed anastrozole, a nonsteroidal AI, as adjuvant therapy following surgery for estrogen and progesterone receptorpositive (ER and PgR+) breast cancer. Methods and sample: A 58-year-old postmenopausal woman diagnosed with ER and PgR+ breast cancer was prescribed anastrozole as adjuvant therapy following a right-inferior quadrantectomy. After experiencing joint pain and stiffness, she was prescribed paracetamol and a topical nonsteroidal anti-inflammatory drug. She was also counseled on nonpharmacological interventions. However, she continued to experience symptoms, and reported that she was not taking anastrozole regularly. Results: The case study patient ultimately found relief by switching to letrozole, another aromatase inhibitor. This approach is supported by recent studies examining the benefits of switching strategies between aromatase inhibitors in order to relieve symptoms of arthralgia/myalgia. Conclusions: Both adherence and strategies for managing aromatase inhibitor-associated arthralgia are key to deriving maximal clinical benefit from AI therapy. Switching from one aromatase inhibitor to another may provide a viable option in managing adverse events and enhancing adherence to medication.

AB - Background: In order to reduce the risk of recurrence, adjuvant treatment with an aromatase inhibitor (AI) is recommended for postmenopausal women following surgery for hormone receptor-positive breast cancer. AIs are associated with improved disease-free survival compared with tamoxifen. The adverse events associated with AIs resemble those of menopause, such as bone density loss and musculoskeletal symptoms. Purpose: We examine the case of a postmenopausal woman who was prescribed anastrozole, a nonsteroidal AI, as adjuvant therapy following surgery for estrogen and progesterone receptorpositive (ER and PgR+) breast cancer. Methods and sample: A 58-year-old postmenopausal woman diagnosed with ER and PgR+ breast cancer was prescribed anastrozole as adjuvant therapy following a right-inferior quadrantectomy. After experiencing joint pain and stiffness, she was prescribed paracetamol and a topical nonsteroidal anti-inflammatory drug. She was also counseled on nonpharmacological interventions. However, she continued to experience symptoms, and reported that she was not taking anastrozole regularly. Results: The case study patient ultimately found relief by switching to letrozole, another aromatase inhibitor. This approach is supported by recent studies examining the benefits of switching strategies between aromatase inhibitors in order to relieve symptoms of arthralgia/myalgia. Conclusions: Both adherence and strategies for managing aromatase inhibitor-associated arthralgia are key to deriving maximal clinical benefit from AI therapy. Switching from one aromatase inhibitor to another may provide a viable option in managing adverse events and enhancing adherence to medication.

KW - Adherence

KW - Anastrozole

KW - Aromatase inhibitor

KW - Arthralgia

KW - Breast cancer

KW - Letrozole

UR - http://www.scopus.com/inward/record.url?scp=84859540098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859540098&partnerID=8YFLogxK

U2 - 10.2147/CMAR.S29448

DO - 10.2147/CMAR.S29448

M3 - Article

C2 - 22570564

AN - SCOPUS:84859540098

VL - 4

SP - 105

EP - 111

JO - Cancer Management and Research

JF - Cancer Management and Research

SN - 1179-1322

IS - 1

ER -